Combined study of Danbio (Denmark) and ARTIS (Sweden) RA registries showed that in 8987 treatment courses of abatacept, rituximab or tocilizumab there was no difference in Serious infection rates - ranging from 4.7-8.1 SIE/100 Pt Yrs. https://t.co/JpYDeSPdpy